Professional
Added to YB: 2025-01-24
Pitch date: 2025-01-23
ACHV [bullish]
Achieve Life Sciences, Inc.
+46%
current return
Author Info
Rogue Funds is a value-oriented hedge fund sharing in-depth analysis. Sign up for the newsletter.
Company Info
Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
Market Cap
$149.2M
Pitch Price
$3.00
Price Target
30.00 (+585%)
Dividend
N/A
EV/EBITDA
-2.09
P/E
-2.00
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
New Study Release is Giving Achieve an Incredible IRR - Achieve Life Sciences, Inc.
ACHV: Cytisinicline for nicotine cessation outperforms Chantix (3.7-6.3 vs 2.88 odds ratio) with fewer side effects. 300-patient 6-month study complete, NDA submission Q2 2025. $300M-$600M revenue potential at 30-60% market share. Valuation potential $15-$30/share. Possible 2025 buyout. PDUFA Oct-Dec if priority review granted.
Read full article (3 min)